XML 26 R11.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Intangible Assets and Goodwill
6 Months Ended
Jun. 30, 2011
Intangible Assets and Goodwill  
Intangible Assets and Goodwill

(7)  Intangible Assets and Goodwill

 

Intangible assets, net of accumulated amortization, and goodwill are as follows:

 

 

 

 

 

June 30, 2011

 

December 31, 2010

 

 

 

Estimated
Life

 

Cost

 

Accumulated
Amortization

 

Net

 

Cost

 

Accumulated
Amortization

 

Net

 

 

 

 

 

(In thousands)

 

Intangible Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

IPR&D

 

Indefinite

 

$

11,800

 

 

$

11,800

 

$

11,800

 

 

$

11,800

 

Amgen Amendment

 

16 years

 

14,500

 

$

(1,570

)

12,930

 

14,500

 

$

(1,121

)

13,379

 

TopoTarget Agreement

 

1.75 years

 

2,400

 

(2,400

)

 

2,400

 

(2,057

)

343

 

Core Technology

 

4.5 - 11 years

 

1,948

 

(1,174

)

774

 

1,948

 

(1,040

)

908

 

Strategic Partner Agreement

 

8 years

 

630

 

(264

)

366

 

630

 

(224

)

406

 

Total Intangible Assets

 

 

 

$

31,278

 

$

(5,408

)

$

25,870

 

$

31,278

 

$

(4,442

)

$

26,836

 

Goodwill

 

Indefinite

 

$

8,965

 

 

$

8,965

 

$

8,965

 

 

$

8,965

 

 

The estimated fair value attributed to the April 2008 agreement (“TopoTarget Agreement”) between the Company (as a successor to CuraGen) and TopoTarget A/S (“TopoTarget”) relates to the Company’s rights under the TopoTarget Agreement to receive up to $6 million in either potential commercial milestone payments related to future net sales of Belinostat or 10% of any sublicense income received by TopoTarget (“TopoTarget Payments”).  In February 2010, TopoTarget entered into a co-development and commercialization agreement for Belinostat with Spectrum Pharmaceuticals, Inc. which resulted in the Company’s receipt of $3 million of the TopoTarget Payments.  The Company recorded this cash receipt as Other Income for the six months ended June 30, 2010.